The Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT) is a collaborative research network with the goal of discovering targeted agents to prevent or intercept the development of cancer in higher-risk populations.
On This Page
- All Heading 2s will automatically be pulled in to this list.
- Do not edit the content on this template.
About the Cancer Prevention-Interception Targeted Agent Discovery Program
The approach to cancer prevention and interception in higher-risk cohorts is to use preventive measures specifically tailored for individual risk factors, an approach referred to as precision cancer prevention-interception. Success of precision cancer prevention-interception depends on two complementary steps:
- First, higher-risk individuals need to be identified, e.g., through screening and early detection of precursors/precancers, some of which may progress to cancer, and testing for genetic susceptibility.
- Second, innovative, safe, and efficacious measures designed to reduce cancer risk or molecularly/immunologically intercept, arrest, and possibly eliminate precancer in these higher-risk individuals are needed to complement or replace surgical resection or ablation.
While current cancer interception strategies predominantly rely on surgical interventions, CAP-IT was created to discover and bring risk-tailored targeted agents to the higher-risk populations for cancer prevention and interception.
The ultimate goals of CAP-IT are to advance newly discovered efficacious cancer preventive or interceptive agents to the existing NCI preclinical and clinical development pipelines: PREVENT Program for further development and Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT) for early phase clinical trials.
View the CAP-IT Network website public webpage.
CAP-IT Teams
CAP-IT at Fox Chase Cancer Center
Principal Investigator (PI)/Admin Core: Margie Clapper, Ph.D.
PI Website: Clapper Lab
Center RePORT: U54 CA272686-01
Institution: The Research Institute of Fox Chase Cancer Center
| Investigator(s) | Role | Lab Page |
|---|---|---|
| Margie Clapper, Ph.D. | Project 1 Lead | Clapper Lab |
| Edna Cukierman, Ph.D. | Project 2 Lead | Cukierman Lab |
| Wen-Chi Chang, Ph.D. | Projects 1&2 Co-investigator | Chang lab |
| Eric Ross, Ph.D., ScM | Informatics Core Lead | Ross Lab |
| Joseph Treat, M.D. | Co-investigator | Treat Lab |
| Erica Golemis, Ph.D. | Co-investigator | Golemis Lab |
| Michael Hall, M.D., M.S. | Co-investigator | Hall Lab |
| Roland L. Dunbrack, Jr, Ph.D. | Administrative core Co-investigator | Dunbrack Lab |
CAP-IT Center for LNP RNA Immunoprevention
Principal Investigator, Project 1 Lead, and Administrative Core Lead: Steven Lipkin, M.D. Ph.D.
PI Website: Lipkin Lab
Center RePORT: U54 CA272688-01
Institution: Weill Medical College of Cornell University
| Investigator(s) | Role | Lab Page |
|---|---|---|
| Naseer Altorki, M.D. | Project 2 Lead | Altorki Lab |
| Timothy McGraw, Ph.D. | Project 2 Co-lead | McGraw Lab |
| Vivek Mittal, Ph.D. | Project 2 Co-lead | Mittal Lab |
| Julie Boyer, Ph.D. | Co-core Lead | Boyer Lab |
| Bhavneet Bhinder, M.S. | Administrative core Co-investigator | Bhinder Lab |
| Olivier Elemento, Ph.D. | Admin core lead/Computational Biology | Elemento Lab |
Institution: German Cancer Research Center (DKFZ) Heidelberg, Germany
| Investigator(s) | Role | Lab Page |
|---|---|---|
| Mathias Kloor, M.D. Ph.D. | Project 1 Co-investigator | Kloor Lab |
| Aysel Ahadova, Ph.D. | Project 1 Co-investigator | Ahadova Lab |
Institution: Sloan Kettering Institute
| Investigator(s) | Role | Lab Page |
|---|---|---|
| Zsofia Stadler, M.D. | Project 1 Co-investigator | Stadler Lab |
Institution: Cornell Engineering
| Investigator(s) | Role | Lab Page |
|---|---|---|
| Shaoyi Jiang, Ph.D. | Projects 1&2 Co-investigator | Jiang Lab |
Institution: Dana-Farber Cancer Institute
| Investigator(s) | Role | Lab Page |
|---|---|---|
| Derin Keskin, Ph.D. | Core Lead | Keskin Lab |
Institution: Broad Institute
| Investigator(s) | Role | Lab Page |
|---|---|---|
| Gad Getz, Ph.D. | Core Co-lead | Getz Lab |
CAP-IT Center Against MGUS Progression
Principal Investigator: Yong Li, Ph.D.
PI Website: Li Lab
Center RePORT: U54 CA272691-01A1
Institution: Baylor College of Medicine
| Investigator(s) | Role | Lab Page |
|---|---|---|
| Xinfang Yu, Ph.D. | Project 2 Lead | Yu Lab |
Institution: University of Arkansas for Medical Sciences
| Investigator(s) | Role | Lab Page |
|---|---|---|
| Fenghuang Zhan, M.D. Ph.D. | Project 1 Lead | Zhan Lab |
| Eric Siegel, M.S. | Project 1 Co-investigator | Siegal Lab |
| John Shaughnessy, Ph.D. | Computational Tumor Immunology Core Lead | Shaughnessy Lab |
| Timothy Ashby, Ph.D. | Co-core Leader | Ashby Lab |
Institution: Duke University
| Investigator(s) | Role | Lab Page |
|---|---|---|
| Ken Young, M.D. Ph.D. | Project 2 Co-investigator | Young Lab |
| Zijun Xu-Monette, Ph.D. | Project 2 Co-investigator | Xu-Monette Lab |
Data and Resource Coordination Center for Cancer Prevention-Interception Targeted Agent Discovery Program
Principal Investigator: Alan Hutson, Ph.D.
PI Website: Hutson Lab
Co-Principal Investigator/MPI: Song Liu, Ph.D.
Co-PI Website: Song Liu Lab
Center RePORT: 3U24CA274159-02S1
Institution: Roswell Park Comprehensive Cancer Center
| Investigator(s) | Role | Lab Page |
|---|---|---|
| Qianqian Zhu, Ph.D. | Co-investigator | Zhu Lab |
| Martin Morgan, Ph.D. | Co-investigator | Morgan Lab |
| Lei Wei, Ph.D. | Co-investigator | Wei Lab |
| Tao Liu, Ph.D. | Co-investigator | Tao Liu Lab |
| Jianmin Wang, Ph.D. | Co-investigator | Wang Lab |
| Mark Long, Ph.D. | Co-investigator | Long Lab |
| Spencer Rosario, Ph.D. | Co-investigator | Rosario Lab |
| Henry Withers, Ph.D. | Co-investigator | Pending |
Institution: University of Nebraska-Lincoln
| Investigator(s) | Role | Lab Page |
|---|---|---|
| Chi Zhang, Ph.D. | Co-investigator | Pending |
Contact the Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT)
Program Contact(s)
Contact CAP-IT
Email: CAP-IT@nih.gov